Skip to main content
. 2023 Apr 27;9(6):835–840. doi: 10.1001/jamaoncol.2023.0181

Figure. Performance and Genomic Features of the HER2DX Pathologic Complete Response (pCR) Score for Predicting pCR Following Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab (THP) Therapy.

Figure.

Receiver operating characteristic curve analysis of the HER2DX pCR score among all patients (A), hormone receptor (HR)–negative patients (B), and HR-positive patients (C). D, Expression of the 4 HER2DX gene expression signatures (immune, proliferation, luminal, and ERBB2 [formerly HER2] amplicon) across the HER2DX pCR score high, medium, and low groups. AUC indicates area under the curve; IGG immunoglobulin G; IHC, immunohistochemistry.